There are nearly 100 million patients with chronic obstructive pulmonary disease (COPD) in China, which is the third most common chronic disease. Hanhui Pharma has a strong product line for COPD and is committed to bringing the world's leading medications to patients in need as quickly as possible, benefiting more patients with COPD in China.
There are nearly 100 million patients with chronic obstructive pulmonary disease (COPD) in China, which is the third most common chronic disease. Hanhui Pharma has a strong product line for COPD and is committed to bringing the world's leading medications to patients in need as quickly as possible, benefiting more patients with COPD in China.
